BUROSUMAB
Slovakia · Košice - mestská časť Západ · how to bid here →
Your path to submission
- Deadline: 23 October at 09:00 — 20 days left.
- You submit on ÚVO / EVO — not here and not by e-mail. ↗
- Collect your evidence — the eligibility requirements are listed above; for many of them the analysis explains how to obtain them.
Clement What the numbers say about this buyer
- In this sector the buyer awards roughly every 4 months (25 awards, most recently September 2026) — the next award is due around January 2027 by that rhythm. The last award went to PHOENIX Zdravotnícke zásobovanie, a.s..n = 25
- 35% of this buyer's awards went to companies that had already won here before (44 awards since 2019, spread over 18 companies). That is well below the sector norm (63%) — this buyer switches suppliers more often than others.n = 44 awards since 2019
- 42% of the bids received came from small and medium-sized enterprises (34 procedures with a bid mix). Sector: 72%.n = 34
- The median procedure drew 2 bids (43 procedures with a bid count); 23% ended with a single bidder. Sector: median 2 bids.n = 43
- The award came in at a median 94% of the estimated value (11 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 91%.n = 11
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 27/09/2026.
Foreign bidders
In Slovakia · Medical equipment & pharma, 17 contracts went to foreign companies over the last 3 years (of 1,850 recorded awards).
Typical field: median 2 (from 25 awards).
What the buyer is looking for
The subject of the contract is the supply of a medicinal product: burosumab 20mg solution for injection and burosumab 30 mg solution for injection with the active substance burosumab, known as Crysvita (‘the product’), for paediatric patients with X-linked hypophosphatemic rickets meeting all of the criteria listed below: 1) with documented high serum concentration of FGF-23 2) with genetically confirmed mutation in PHEX gene 3) persistence of low hypophosphataemia despite long-term substitution by maximum tolerated doses of phosphate solution and active form of vitamin D 4) in progression of bone deformities despite administration of maximum tolerated doses of standard therapy (phosphates and vitamin D).
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| MED - ART, spol. s r.o. | 9 | 2024–2025 |
| PHOENIX Zdravotnícke zásobovanie, a.s. | 4 | 2024–2026 |
| Stargen EU s.r.o. | 3 | 2025 |
| Up Déjeuner, s. r. o. | 2 | 2024–2026 |
| AGB ekoservis s.r.o. | 2 | 2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.